CSL Behring engaged Milliman to analyze the implications for individual Medicare Part D spending if plasma therapies were subject to a phase-in of liability for the manufacturer discount program. The Build Back Better Act, also known as H.R. 5376, proposed the phase-in, and we analyzed the possible two key relevant provisions to Part D, which address benefit redesign and cost sharing for insulin products.

This paper was commissioned by CSL Behring.